Dengue Fever – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Dengue Fever – Pipeline Review, H2 2017’, provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dengue Fever

The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dengue Fever therapeutics and enlists all their major and minor projects

The report assesses Dengue Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dengue Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Altravax Inc

Biological Mimetics Inc

Bioneer Corp

Biotron Ltd

Chugai Pharmaceutical Co Ltd

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

GeneSegues Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Hawaii Biotech Inc

Immunotope Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Merck & Co Inc

Novartis AG

NovaTarg Therapeutics Inc

Panacea Biotec Ltd

Plex Pharmaceuticals Inc

Shionogi & Co Ltd

SIGA Technologies Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

Themis Bioscience GmbH

Visterra Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Dengue Fever Overview 5

Dengue Fever Therapeutics Development 6

Dengue Fever Therapeutics Assessment 19

Dengue Fever Companies Involved in Therapeutics Development 27

Dengue Fever Drug Profiles 41

Dengue Fever Dormant Projects 141

Dengue Fever Discontinued Products 145

Dengue Fever Product Development Milestones 146

Appendix 156

List of Tables

List of Tables

Number of Products under Development for Dengue Fever, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dengue Fever Pipeline by Abivax SA, H2 2017

Dengue Fever Pipeline by Altravax Inc, H2 2017

Dengue Fever Pipeline by Biological Mimetics Inc, H2 2017

Dengue Fever Pipeline by Bioneer Corp, H2 2017

Dengue Fever Pipeline by Biotron Ltd, H2 2017

Dengue Fever Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Dengue Fever Pipeline by Emergent BioSolutions Inc, H2 2017

Dengue Fever Pipeline by Ennaid Therapeutics LLC, H2 2017

Dengue Fever Pipeline by GeneSegues Inc, H2 2017

Dengue Fever Pipeline by GlaxoSmithKline Plc, H2 2017

Dengue Fever Pipeline by Globavir Biosciences Inc, H2 2017

Dengue Fever Pipeline by Hawaii Biotech Inc, H2 2017

Dengue Fever Pipeline by Immunotope Inc, H2 2017

Dengue Fever Pipeline by Indian Immunologicals Ltd, H2 2017

Dengue Fever Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Dengue Fever Pipeline by Johnson & Johnson, H2 2017

Dengue Fever Pipeline by Kineta Inc, H2 2017

Dengue Fever Pipeline by Merck & Co Inc, H2 2017

Dengue Fever Pipeline by Novartis AG, H2 2017

Dengue Fever Pipeline by NovaTarg Therapeutics Inc, H2 2017

Dengue Fever Pipeline by Panacea Biotec Ltd, H2 2017

Dengue Fever Pipeline by Plex Pharmaceuticals Inc, H2 2017

Dengue Fever Pipeline by Shionogi & Co Ltd, H2 2017

Dengue Fever Pipeline by SIGA Technologies Inc, H2 2017

Dengue Fever Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Dengue Fever Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Dengue Fever Pipeline by TechnoVax Inc, H2 2017

Dengue Fever Pipeline by Themis Bioscience GmbH, H2 2017

Dengue Fever Pipeline by Visterra Inc, H2 2017

Dengue Fever Pipeline by VLP Therapeutics LLC, H2 2017

Dengue Fever Dormant Projects, H2 2017

Dengue Fever Dormant Projects, H2 2017 (Contd..1), H2 2017

Dengue Fever Dormant Projects, H2 2017 (Contd..2), H2 2017

Dengue Fever Dormant Projects, H2 2017 (Contd..3), H2 2017

Dengue Fever Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Dengue Fever, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports